Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug
[ad_1]
Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.
[ad_2]
Source link
[ad_1]
Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.
[ad_2]
Source link